Literature DB >> 28505305

Efficacy and Safety of Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C in Persons With Sickle Cell Disease.

Juhi Moon1, Robert H Hyland2, Fangqiu Zhang2, Diana M Brainard2, Sophie Lanzkron1, John G McHutchison2, Mark Sulkowski1.   

Abstract

Patients with sickle cell disease are at high risk for chronic hepatitis C infection. Prior treatment has been limited due to the use of ribavirin causing hemolytic anemia and interferon causing cytopenias. We demonstrate the safety and efficacy of fixed-dose combination ledipasvir and sofosbuvir for 12 weeks in this population.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HCV; LDV/SOF; hepatitis C infection; ledipasvir; sickle cell disease

Mesh：

Substances：

Year:  2017        PMID： 28505305      PMCID： PMC6248462          DOI： 10.1093/cid/cix441

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  10 in total

1.  Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.

Authors:  Norah A Terrault; Stefan Zeuzem; Adrian M Di Bisceglie; Joseph K Lim; Paul J Pockros; Lynn M Frazier; Alexander Kuo; Anna S Lok; Mitchell L Shiffman; Ziv Ben Ari; Lucy Akushevich; Monika Vainorius; Mark S Sulkowski; Michael W Fried; David R Nelson
Journal:  Gastroenterology       Date:  2016-08-24       Impact factor: 22.682

2.  A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus.

Authors:  Amit G Singal; Michael L Volk; Donald Jensen; Adrian M Di Bisceglie; Philip S Schoenfeld
Journal:  Clin Gastroenterol Hepatol       Date:  2009-11-27       Impact factor: 11.382

3.  A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.

Authors:  G Fattovich; G Giustina; S Favarato; A Ruol
Journal:  J Hepatol       Date:  1996-01       Impact factor: 25.083

4.  Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.

Authors:  Bart J Veldt; E Jenny Heathcote; Heiner Wedemeyer; Juerg Reichen; W Peter Hofmann; Stefan Zeuzem; Michael P Manns; Bettina E Hansen; Solko W Schalm; Harry L A Janssen
Journal:  Ann Intern Med       Date:  2007-11-20       Impact factor: 25.391

5.  Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

Authors:  John G McHutchison; Michael Manns; Keyur Patel; Thierry Poynard; Karen L Lindsay; Christian Trepo; Jules Dienstag; William M Lee; Carmen Mak; Jean-Jacques Garaud; Janice K Albrecht
Journal:  Gastroenterology       Date:  2002-10       Impact factor: 22.682

Review 6.  Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis.

Authors:  Ashwani K Singal; Amanpal Singh; Sathya Jaganmohan; Praveen Guturu; Rajasekhara Mummadi; Yong-Fang Kuo; Gagan K Sood
Journal:  Clin Gastroenterol Hepatol       Date:  2009-10-30       Impact factor: 11.382

7.  Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.

Authors:  Kris V Kowdley; Stuart C Gordon; K Rajender Reddy; Lorenzo Rossaro; David E Bernstein; Eric Lawitz; Mitchell L Shiffman; Eugene Schiff; Reem Ghalib; Michael Ryan; Vinod Rustgi; Mario Chojkier; Robert Herring; Adrian M Di Bisceglie; Paul J Pockros; G Mani Subramanian; Di An; Evguenia Svarovskaia; Robert H Hyland; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; David Pound; Michael W Fried
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

8.  Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

Authors:  Nezam Afdhal; Stefan Zeuzem; Paul Kwo; Mario Chojkier; Norman Gitlin; Massimo Puoti; Manuel Romero-Gomez; Jean-Pierre Zarski; Kosh Agarwal; Peter Buggisch; Graham R Foster; Norbert Bräu; Maria Buti; Ira M Jacobson; G Mani Subramanian; Xiao Ding; Hongmei Mo; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Alessandra Mangia; Patrick Marcellin
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245

Review 9.  HCV in sickle cell disease.

Authors:  Mohamed Hassan; Syed Hasan; Oswaldo Castro; Samuel Giday; Alpha Banks; Duane Smoot
Journal:  J Natl Med Assoc       Date:  2003-09       Impact factor: 1.798

10.  Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Authors:  Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245
  10 in total
  2 in total

Review 1.  Management of liver complications in sickle cell disease.

Authors:  Abid R Suddle
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 2.  Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update.

Authors:  Elise J Smolders; Anouk M E Jansen; Peter G J Ter Horst; Jürgen Rockstroh; David J Back; David M Burger
Journal:  Clin Pharmacokinet       Date:  2019-10       Impact factor: 6.447
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.